Stockscreener 앱 받기
0.185
16.95%
-0.0351
전일 마감가:
$0.2201
열려 있는:
$0.205
하루 거래량:
47.29M
Relative Volume:
0.55
시가총액:
$48.66M
수익:
$175.04M
순이익/손실:
$-44.52M
주가수익비율:
-1.0278
EPS:
-0.18
순현금흐름:
$-56.05M
1주 성능:
+19.09%
1개월 성능:
+259.84%
6개월 성능:
-14.98%
1년 성능:
-79.20%
1일 변동 폭
$0.178
$0.214
1주일 범위
$0.1309
$0.275
52주 변동 폭
$0.0403
$0.9116
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile
명칭
Adaptimmune Therapeutics Plc Adr
전화
44 1235 430000
주소
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
ADAP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADAP
Adaptimmune Therapeutics Plc Adr
|
0.1836 | 58.34M | 175.04M | -44.52M | -56.05M | -0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.71 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.97 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.30 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.62 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
322.43 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-06-26 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-07-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-30 | 개시 | Scotiabank | Sector Outperform |
| 2023-03-24 | 개시 | Bryan Garnier | Buy |
| 2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-11-09 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-05-28 | 개시 | Barclays | Underweight |
| 2020-04-22 | 개시 | Mizuho | Neutral |
| 2019-08-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-05-31 | 개시 | ROTH Capital | Buy |
| 2019-05-30 | 재개 | Citigroup | Buy |
| 2019-05-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2017-03-17 | 개시 | Wells Fargo | Market Perform |
| 2016-10-24 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2016-09-30 | 개시 | Raymond James | Outperform |
| 2016-02-25 | 개시 | Citigroup | Buy |
| 2015-06-01 | 개시 | BofA/Merrill | Neutral |
| 2015-06-01 | 개시 | Guggenheim | Buy |
| 2015-06-01 | 개시 | Leerink Partners | Outperform |
모두보기
Adaptimmune Therapeutics Plc Adr 주식(ADAP)의 최신 뉴스
Pre-Market Titans: TTRX, BJDX & UPC Set The Pace - RTTNews
Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback? - ts2.tech
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real? - ts2.tech
Morning Market Movers: FEMY, PALI, COSM, Seeing Big Swings - RTTNews
Morning Market Movers: MRM, LEXX, WOLF See Big Swings - RTTNews
Stocks Moving Premarket: PEPG, WOK, ICU, And Other Gainers & Losers - RTTNews
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC - Yahoo Finance
Must-Watch Streaming Stocks Poised to Gain From Content Boom - Yahoo Finance
Is Hesai Group Sponsored ADR (HSAI) Outperforming Other Auto-Tires-Trucks Stocks This Year? - Yahoo Finance
Lenovo Finds 65% of IT Leaders Admit Their Defenses Can’t Withstand AI Cybercrime - Yahoo Finance
Why the Market Dipped But Li Auto Inc. Sponsored ADR (LI) Gained Today - Yahoo Finance
What Does Wall Street Think About Li Auto Inc. (LI)? - Yahoo Finance
Vestas Wind Systems AS ADR (VWDRY) Wind Turbines Orders on the Rise - Yahoo Finance
The Zacks Analyst Blog Highlights Walmart, Alibaba, Shell, Omega Flex and Weyco - Yahoo Finance
Investors Take Advantage Of 15.76% Gain In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - stocksregister.com
What Is Going On With Top KingWin Ltd (NASDAQ: WAI)? - stocksregister.com
Rio Tinto plc ADR Common Stock (RIO) Restructures to Focus on Profitable Assets - Yahoo Finance
Zacks.com featured highlights include Halozyme Therapeutics, Phibro, Leidos and PDD Holdings - Yahoo Finance
Adaptimmune Therapeutics CFO Wood sells $950 in shares - Investing.com
Nio Inc. ADR (NIO) Upgraded to ‘Overweight’ at JPMorgan on Strong Vehicle Demand - Yahoo Finance
Earnings call transcript: Adaptimmune Q2 2025 shows revenue beat, stock dips - Investing.com
Questex’s Fierce Pharma Week Announces Star-Studded Lineup with Jamie-Lynn Sigler, James Van Der Beek, Selma Blair, Kelly Killoran Bensimon and John Duffield to Provide Powerful Stories of Resilience and Healing - GlobeNewswire Inc.
Adaptimmune director Behbahani sells shares worth $229,171 - Investing.com
Are Investors Undervaluing ENGIESponsored ADR (ENGIY) Right Now? - Yahoo Finance
Adaptimmune Faces Nasdaq Delisting Notice Amid Compliance Issues - MSN
Adaptimmune Sales Jump 59 Percent - sharewise.com
Is Piedmont Lithium Inc.Sponsored ADR (PLL) Stock Outpacing Its Basic Materials Peers This Year? - Yahoo Finance
ADAP’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - Yahoo Finance
Wall Street Today: Dow, Nasdaq, S&P 500 open higher as investors focus on optimism over potential US Fed rate cut - Mint
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Ecor1 capital sells Adaptimmune Therapeutics (ADAP) shares for $6.89m - Investing.com India
Adaptimmune stock rating downgraded by H.C. Wainwright after asset sale - Investing.com South Africa
Adaptimmune Therapeutics stock plunges after selling cell therapy assets By Investing.com - Investing.com India
Adaptimmune Therapeutics stock plunges after selling cell therapy assets - Investing.com
Adaptimmune sells cell therapy assets to US WorldMeds for $55 million - Investing.com
XPeng Inc. Sponsored ADR (XPEV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect - Yahoo Finance
Mizuho downgrades Adaptimmune stock on solvency concerns - Investing.com
Financial Metrics Unveiled: MARA Holdings Inc (MARA)’s Key Ratios in the Spotlight - DWinneX
Best Momentum Stocks to Buy for June 12th - Yahoo Finance
Context Therapeutics names new CMO to advance T cell therapies By Investing.com - Investing.com South Africa
Context Therapeutics names new CMO to advance T cell therapies - Investing.com
KANZHUN LIMITED Sponsored ADR (BZ) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Adaptimmune Therapeutics earnings beat by $0.09, revenue fell short of estimates - Investing.com UK
Healthy Upside Potential: Merus N.V (MRUS) - Sete News
How should investors view Jianzhi Education Technology Group Co Ltd ADR (JZ)? - uspostnews.com
CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105 - Yahoo Finance
All Markets & Instruments Available to Trade - Capital.com
Adaptimmune Therapeutics Plc ADR’s (ADAP) Stock Is Harder To Predict Than You Think - Stocksregister
Take off with Adaptimmune Therapeutics Plc ADR (ADAP): Get ready for trading - Sete News
Adaptimmune Therapeutics Plc Adr (ADAP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.39%
자본화:
|
볼륨(24시간):